Prognostic impact of cytogenetic abnormalities in newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous stem-cell transplantation: A prospective analysis of 593 patientsElena Zamagni, Michèle Cavo, Patrizia Tosi et al.|F1000Research|2010Cited by 0
Final analysis of the multicenter phase II "Bologna 2002" study incorporating thalidomide-dexamethasone (thal-dex) into up-front double autologous stem-cell transplantation (ASCT) for multiple myelomaElena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Unknown|2009Cited by 0